Back

Effects of pharmacological inhibition of Sphingosine Kinase 1 on cardiovascular function in angiotensin II-dependent hypertension in vivo

26 August 2018 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 2 - Pulmonary hypertension Drugs, Drug Targets ESC Premium Access ESC Congress 2018

About the speaker

Photo
Ms Ewelina Jozefczuk

Jagiellonian University Medical College, John Paul II Hospital, Krakow (Poland)

7 More presentations in this session

Presentation thumbnail
Mr W. Zhuang (Fuzhou, CN)
Abstract Slides
Presentation thumbnail
Mr M. Markov (Moscow, RU)
Abstract Slides
Presentation thumbnail
Professor S. Sung (Taipei, TW)
Abstract
Presentation thumbnail
Doctor Y. Kono (Yamanashi, JP)
Abstract Slides
Presentation thumbnail
Doctor D. Kinoshita (Yamagatz, JP)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Pulmonary hypertension

The Event

Event poster

ESC Congress 2018

26 August 2018 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Targeted modulation of sphingolipid signaling to inhibit the progression of aortic valve disease
31 August 2025
thumbnail
Congress Presentation
Empagliflozin treatment does not affect the hypertensive response to Ang II administration to rats but decreases oxidative stress in the arterial wall, and endothelial and cardiac dysfunction
1 September 2020
thumbnail
Congress Session
From genetic signatures to clinical implications
18 May 2025
thumbnail
Congress Presentation
Cardiac S1P/Ceramide imbalance in human heart failure: implication of gene dysregulation
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources